✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
Key Takeaways — Ozempic Cost in 2026
- US list price (Novo Nordisk): approximately $968 per 28-day pen, regardless of dose strength. Wegovy is approximately $1,349/month; Rybelsus oral is approximately $985/month.
- With commercial insurance + savings card (diabetes indication), out-of-pocket can be as low as $25/month. Without insurance, expect $968+ at retail.
- Medicare cannot cover Ozempic for weight loss — only for type 2 diabetes. The Inflation Reduction Act caps Part D semaglutide out-of-pocket at $2,000/year starting 2026 for diabetes use.
- The cheapest path is structural, not negotiating: insurance + manufacturer card if eligible; oral semaglutide if injection isn’t required; tirzepatide if response is inadequate; international supply for non-US patients.
- Compounded semaglutide is no longer legal in the US for general use after the FDA shortage exit in February 2025. Beware operators still advertising it.
What Ozempic Actually Costs at the Pharmacy Counter
The headline number on every cost article is the manufacturer list price. That number rarely matches what an actual patient pays. To get to a useful answer, we need to separate four distinct prices:
- List price — what Novo Nordisk publishes (“WAC”). This is the starting point for negotiations.
- Cash price — what an uninsured patient pays at retail (often within 10% of list at chain pharmacies, lower at warehouse and discount pharmacies).
- Negotiated insurance price — what the insurer pays after PBM rebates; usually 20–35% below list. Patient does not see this number.
- Patient out-of-pocket — what the patient writes a check for. This is co-pay + deductible activity, not the underlying price.
2026 Ozempic, Wegovy, and Rybelsus Prices
| Drug | List price (US, 2026) | Insured patient (savings card) | Cash floor |
|---|---|---|---|
| Ozempic (any dose) | ~$968 / 28-day pen | $25/month (commercial) | ~$815 (Costco) |
| Wegovy 2.4 mg | ~$1,349 / 28 days | $0–$225/month (NovoCare) | ~$1,300 |
| Rybelsus 14 mg | ~$985 / 30-day supply | $10/month (commercial) | ~$830 |
| Mounjaro (tirzepatide) | ~$1,069 / 4-pen box | $25/month (commercial) | ~$900 |
| Zepbound (tirzepatide weight-loss label) | ~$1,059 / 4-pen box | $25–$650/month | ~$550 (Lilly Direct vials) |
Numbers reflect Novo Nordisk and Eli Lilly published prices and KFF/GoodRx tracker data for early 2026. Cash prices vary by chain — Costco, Sam’s Club, and Mark Cuban’s Cost Plus Drugs typically come in 10–20% below CVS/Walgreens for the same drug.
How Insurance Actually Works for Ozempic
Three big insurance variables
- Indication. Plans cover semaglutide for type 2 diabetes far more often than for weight management. Diabetes ICD-10 codes (E11.x) are usually approved; obesity codes (E66.x) often hit step-therapy or denial.
- Formulary tier. Ozempic is typically Tier 2 or Tier 3 (specialty) on most commercial formularies. That sets the co-pay structure but not the absolute cost.
- Prior authorisation. Most plans require PA documenting failed metformin (for diabetes) or BMI ≥ 30 with comorbidities (for weight management).
The Novo Nordisk Savings Card
For commercially insured patients with type 2 diabetes whose plan covers Ozempic, the Novo Nordisk Diabetes Savings Card reduces out-of-pocket to $25 per 1, 2, or 3 month prescription. Eligibility:
- Commercial insurance (NOT Medicare, Medicaid, or any government plan).
- Plan must cover Ozempic (PA approved).
- US resident.
- Maximum savings $150/month, $1,800/year.
The card does not work if your plan does not cover Ozempic — it offsets your share, not the full price. Many patients incorrectly believe the card brings cash patients to $25; it does not.
NovoCare Patient Assistance Programme
For patients without insurance who meet income criteria (≤ 400% Federal Poverty Level for most products), NovoCare can supply Ozempic free of charge. The application requires income documentation and prescriber sign-off; processing is 2–4 weeks. Many uninsured patients underestimate their eligibility.
Medicare and Medicaid Reality
Medicare Part D explicitly excludes weight-loss drugs by statute. Ozempic can therefore only be Part D-covered for the diabetes indication. Patients prescribed Ozempic for obesity without diabetes will hit denial. The Inflation Reduction Act caps total Part D out-of-pocket at $2,000/year starting 2026, which is meaningful for diabetic Ozempic users — they will hit the cap on prescription drugs and pay nothing thereafter.
Medicaid coverage varies by state. About 20 states explicitly cover anti-obesity medications under Medicaid (CMS guidance updated 2024); the remainder cover semaglutide only for diabetes. Check your specific state Medicaid formulary.
Tricare and VA generally cover Ozempic for diabetes; weight-loss coverage is restricted and varies by service.
The Compounded Semaglutide Question
From mid-2022 through early 2025 the FDA listed Ozempic and Wegovy as in shortage. During that window 503A compounding pharmacies and 503B outsourcing facilities legally compounded semaglutide for individual patients, typically at $250–$500/month. Many telehealth platforms (Hims, Ro, Sequence, Found, etc.) built their offerings on this pathway.
This pathway closed. FDA officially declared the shortage resolved in February 2025. The agency gave 60–90 days of enforcement discretion, then ended that window. As of mid-2025 onward, large-scale compounding of semaglutide for general weight loss is no longer legal in the United States. Narrow exceptions remain for individual clinical needs that the FDA-approved product cannot meet (e.g. confirmed allergy to a specific excipient).
What this means for cost in 2026:
- Telehealth platforms that built around compounded semaglutide have either pivoted to brand-name prescriptions (at brand-name prices) or to alternative compounded molecules.
- Operators still advertising “compounded semaglutide” at $250–$500/month are increasingly offshore or operating outside FDA enforcement scope. Buyer beware.
- The previous 60–80% discount path is closed; patients are pushed back into the brand-name + insurance system or to international alternatives.
International Pricing — Why Ozempic Is Cheaper Almost Everywhere Else
Single-payer healthcare systems negotiate national list prices that the US does not. Ozempic is the same molecule in every country; the price difference is purchasing power and policy.
| Country | Approx local price | USD equivalent |
|---|---|---|
| United States | $968 / pen | $968 |
| United Kingdom (NHS) | £73 / pen | ~$92 |
| Germany | €90 / pen | ~$98 |
| Australia (PBS) | A$130 / pen | ~$87 |
| Canada | C$280 / pen | ~$210 |
| India | ₹4,500 / pen | ~$54 |
US patients sometimes ask whether they can mail-order Ozempic from Canada or Mexico. The legal answer is complex: personal-use importation of small quantities for self-administration is routinely tolerated by FDA but technically not permitted; the FDA can seize parcels. Patients who pursue this pathway accept that risk.
The Practical Cost-Reduction Menu
Ranked from largest to smallest typical cost reduction:
- Get on your plan’s covered tier with PA approved. If your plan covers Ozempic for diabetes, the Novo savings card brings you to $25/month. This is the single biggest lever for most US patients.
- Switch to oral semaglutide if injection isn’t critical. Same molecule. Cash price ~15% lower; insurance treats it differently and may have lower co-pays.
- Switch to tirzepatide via Lilly Direct. Eli Lilly offers tirzepatide vials (not pens) directly to cash patients via LillyDirect.com at ~$550/month for higher doses — significantly below Zepbound pen pricing.
- Use Costco, Sam’s Club, or Cost Plus Drugs. These chains routinely come in 10–20% under standard retail. No insurance required.
- Apply to NovoCare patient assistance if uninsured and under 400% FPL. Free Ozempic if eligible.
- Source non-Ozempic alternatives internationally for non-US patients or for patients seeking semaglutide alternatives. See our Ozempic alternatives hub. On the brand-versus-compounded-versus-research-grade economics, our Ozempic vs Generic Semaglutide head-to-head covers the per-mg supply-chain math; for the non-diabetic off-label use case specifically, where weight-loss insurance authorisation is harder and the cost structure shifts, see our Ozempic for non-diabetics guide.
Why Cash Price Hasn’t Come Down Despite Tirzepatide Competition
Conventional economic theory predicts that competition lowers prices. With Mounjaro and Zepbound (tirzepatide) on the market since 2022 and showing better weight-loss outcomes than semaglutide, cash price for Ozempic should have fallen. It has not. Three reasons:
- Supply-constrained category. Through 2024 there were not enough GLP-1 doses in the world to meet demand. Producers had no incentive to compete on price.
- Insurance-mediated pricing. Most US revenue flows through PBM rebates rather than cash. Producers compete on net rebated price to insurers, not list-price-to-patient.
- Brand stickiness. Patients who tolerated Ozempic well rarely switch unless forced; doctors prescribe what they prescribed last quarter; insurance formularies favour incumbents.
The 2025 IRA caps and the Lilly Direct cash-vials pricing model are early signs that this could shift in 2026–2027. For now, list prices remain sticky.
Where to Get Lower-Cost Semaglutide Alternatives at MedsBase
MedsBase doesn’t sell brand-name Ozempic injection pens — cold-chain, biologic and import-Rx rules make reliable cross-border shipping of pens impractical. We do supply the broader GLP-1 alternatives bench, including oral semaglutide, tirzepatide, retatrutide research-grade peptide (from $310), liraglutide, and orlistat — all sourced from WHO-GMP certified manufacturers and shipped worldwide.
Browse the weight-loss category for in-stock SKUs. All orders covered by our Reshipment Assurance Policy; statements show the regulated processor (a regulated card-payment processor), never MedsBase. For the wider Ozempic context — molecule, indications, dose titration, side effects, and the complete buying-and-alternatives map — see our Ozempic Buying Guide.
Frequently Asked Questions
How much does Ozempic cost without insurance in 2026?
About $968 per 28-day pen at standard US retail (CVS, Walgreens). Costco and Sam’s Club typically run $815–$840. Mark Cuban Cost Plus Drugs: ~$830. Same drug, varying retail margin.
How much does Ozempic cost with insurance?
With commercial insurance plus the Novo Nordisk savings card, out-of-pocket can be as low as $25 per 1-, 2-, or 3-month prescription — but only for the diabetes indication. Without the card, a typical co-pay on a Tier 2 specialty drug is $50–$150/month.
Why doesn’t Medicare cover Ozempic for weight loss?
Federal statute (Social Security Act §1860D-2(e)) excludes “drugs for weight loss” from Part D coverage. Ozempic can be Medicare-covered only when prescribed for type 2 diabetes (which it is FDA-approved for); off-label use for obesity in patients without diabetes is excluded by law, not by individual plan choice.
Is compounded semaglutide still available cheaper?
Not legally in the US for general use. The FDA officially resolved the Ozempic and Wegovy shortages in February 2025, ending the 503A/503B compounding window. Operators still advertising compounded semaglutide are typically offshore or operating outside FDA enforcement. Buyer should evaluate carefully.
Is Wegovy cheaper than Ozempic?
No — Wegovy is more expensive ($1,349 vs $968 per month list). Wegovy is FDA-approved specifically for chronic weight management and contains a higher 2.4 mg dose; Ozempic is the same molecule at lower diabetic doses. Patients who can document a diabetes ICD-10 are usually steered to Ozempic for the lower price.
What’s the cheapest semaglutide option overall?
For US patients with commercial insurance + diabetes coverage: $25/month with the Novo savings card. Without insurance: oral semaglutide (Rybelsus) at warehouse-pharmacy cash price is typically the cheapest legitimate semaglutide pathway. For non-US patients, international supply through pharmacies like MedsBase is generally meaningfully cheaper than US retail.
Will Ozempic ever go generic?
The composition-of-matter patents on semaglutide expire 2031–2032. Realistic generic launch in the US is 2031 at earliest, possibly later because Novo holds additional formulation patents. Generic semaglutide injection pens are already approved and launching in lower-IP-protection markets like India and China.
Why is Ozempic so much cheaper in other countries?
Single-payer health systems in the UK, Germany, Australia, and Canada negotiate national list prices on behalf of all patients in the country. Novo Nordisk accepts those prices to maintain market access. The US has no equivalent national negotiation; list price reflects what individual PBMs and insurers will pay after rebates, which is much higher.
Pricing Disclaimer: Prices reflect Novo Nordisk and Eli Lilly published list prices, KFF and GoodRx tracker data, and savings programmes as of early 2026. Real out-of-pocket varies with insurance plan, geography, and pharmacy. This article is educational and is not a substitute for personalised pricing or medical advice. Coverage rules and prices change — verify current pricing at the pharmacy or insurer of your choice.
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.